CIPLA LTD vs DR. LAL PATH LABS LTD.

A side-by-side comparison of CIPLA LTD (CIPLA) and DR. LAL PATH LABS LTD. (LALPATHLAB) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

CIPLA LTD and DR. LAL PATH LABS LTD. are evenly matched on the numbers (77). The breakdown below shows where each one wins.

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.54
P/E ratio
56.00
3.42
P/B ratio
11.26
0.90%
Dividend yield
1.22%
₹48.02
EPS
₹30.13

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
22.50%
15.00%
Return on capital
28.00%
21.00%
EBITDA margin
28.00%
13.71%
Net margin
18.46%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
11.06%
10.88%
Profit CAGR (3Y)
28.39%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.15L Cr
Market cap
₹28,262 Cr
₹28,163 Cr
Revenue
₹2,763 Cr
₹3,862 Cr
Net profit
₹510 Cr
0.02
Debt / equity
0.08
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
DR. LAL PATH LABS LTD.
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 36.4%"]
  • ["Stock is trading at 11.3 times its book value", "The company has delivered a poor sales growth of 11.8% over past five years."]
CIPLA LTD full analysis DR. LAL PATH LABS LTD. full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.